C50
Conditions
Interventions
Group 1: Patients with non-metastatic breast cancer: Determination of CETC from serum (maintrac method) on the first irradiation day, both half of the fractions, on the last irradiation day, and 6 wee
Sponsors
Transfusionsmedizinisches Zentrum Bayreuth, Labor Dr. Pachmann Bayreuth
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: • histologically confirmed invasive breast carcinoma • age >= 18 years • exclusive treatment at the Jena University Hospital • Complete curative-intended adjuvant or definite radiotherapy (achieved total dose = 50 Gy normo- or hypofraction) • at least 3 blood samples (before the start of therapy, half of the fractions, after the end of RT, 6 weeks after the end of RT) • Dose concepts: Hypofraction up to 42.56 (2.66) Gy, normofraction to 50.0 (2.0) Gy followed by a boost up to 16.0 Gy, 5 Fx / week
Exclusion criteria
Exclusion criteria: • Lack of willingness to consent • Presence of metastases • Recurrence • DCIS, inflammatory breast carcinoma • Second malignancy <10 years before diagnosis of breast cancer • Radiation therapy in anamnesis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of CETCs on the first irradiation day, half of the fractions, on the last irradiation day, and 6 weeks after end of radiation therapy (maintrac), overall survival (follow up on cancer registries after 3 & 5 years) disease-free survival 3 & 5 years) | — |
Secondary
| Measure | Time frame |
|---|---|
| Effect of non-steroidal anti-inflammatory drugs (NSAID) on the growth behavior of tumorspheres | — |
Countries
Germany
Contacts
Public ContactMatthias Mäurer
Klinik für Strahlentherapie und Radioonkologie Jena
Outcome results
None listed